cangrelor
Ligand Summary
Cangrelor is a direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signaling and platelet activation.
UNII: 6AQ1Y404U7
PubChem: 10260031
PubChem: 9854012
Guide to Pharmacology: 1776
ChEMBL: CHEMBL1097279
ChEMBL: CHEMBL334966
DrugCentral: 5006
LyCHI: 2PP7NP1N8QA6
Target Activities
P2RY12
P2Y purinoceptor 12
8 Activities
Items per page:
1 – 8 of 8
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
- | 8 | |||||
IC50 | 9.4 | |||||
IC50 | 9.4 | J. Med. Chem., (2002) 45:19:4057 | ||||
IC50 | 9.4 | Bioorg. Med. Chem. Lett., (2016) 26:12:2739 | ||||
IC50 | 9.15 | J. Med. Chem., (2010) 53:9:3489 | ||||
IC50 | 8.7 | Bioorg. Med. Chem., (2015) 23:14:3880 | ||||
IC50 | 7.74 | Eur. J. Med. Chem., (2016) 107:None:204 | ||||
IC50 | 8.63 | ANTAGONIST | ||||
GPR17
Uracil nucleotide/cysteinyl leukotriene receptor
2 Activities
P2RY13
P2Y purinoceptor 13
2 Activities
Items per page:
1 – 2 of 2
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) | ||
|---|---|---|---|---|---|---|
- | 8.3 | |||||
IC50 | 8.3 | ANTAGONIST | ||||